ECEESPE2025 ePoster Presentations Endocrine Related Cancer (100 abstracts)
1Rigshospitalet, Department of Nephrology and Endocrinolgy, Copenhagen, Denmark; 2Rigshospitalet, Department of Oncology, Copenhagen, Denmark
JOINT2200
Introduction: Endocrine side effects to breast cancer treatment become more prevalent as survival rates increase making it relevant to know if, when and how to treat. Previously studies described a negative effect of chemotherapy on metabolism such as weight gain and an increased incidence of the diagnosis of type 2 diabetes.
Materials and Methods: We aimed to exploratively describe selected endocrine areas in postmenopausal women with non-metastatic breast cancer focusing on glucose, thyroid and calcium metabolism. Relevant blood samples were collected at baseline immediately before chemotherapy and after completing chemotherapy. Patients were compared to healthy controls at baseline.
Results: 95 patients of which 64 were fasting had higher BMI before chemotherapy, higher fasting plasma glucose, fasting C-peptide and higher HOMA-IR compared to controls. Fasting plasma glucose and fasting C-peptide were still significantly higher in patients when adjusted for BMI. After chemotherapy patients had lower ionized calcium and free T4 and higher levels of parathyroid hormone and 25-OH-Vitamin-D. No significant change was seen in blood test relevant for the glucose metabolism.
Conclusions: At baseline patients already show signs of impaired glucose metabolism compared to controls. Chemotherapy doesnt appear to change parameters of glucose metabolism. After chemotherapy changes are seen in thyroid and calcium metabolism though changes are interpreted as having no clinical significance.